سامانه کنگره های دانشگاه علوم پزشکی و خدمات بهداشتی و درمانی آذربایجان غربی

صفحه اصلی / بیستمین همایش سالیانه بیماری های شایع گوارش و کبد کودکان ایران و دومین همایش بین المللی چاقی کودکان

The Efficacy of Probiotics in Managing Irritable Bowel Syndrome (IBS) in Children A Prospective Cohort Study (2022–2024)

نویسندگان :

Aydin Mahmoud Alilou¹ Roghayeh Faraji Akhijahani² Omid Kazemi³ Mohaddeseh Masoumi⁴ Ali Bayani⁵ Neda Jalizi⁶ Pardis Pour Ali⁷ Pouria Shieeh⁸ Alisan Khodayarlo⁹ Sina Manouchehrnia¹⁰ Sana Nasirpour¹¹ Meysam Najafi¹²

1- دانشگاه علوم پزشکی تبریز 2- دانشگاه علوم پزشکی تبریز 3- دانشگاه علوم پزشکی تبریز 4- دانشگاه علوم پزشکی تبریز 5- دانشگاه علوم پزشکی تبریز 6- دانشگاه علوم پزشکی تبریز 7- دانشگاه علوم پزشکی تبریز 8- دانشگاه علوم پزشکی تبریز 9- دانشگاه علوم پزشکی تبریز 10- دانشگاه علوم پزشکی تبریز 11- دانشگاه علوم پزشکی تبریز 12- دانشگاه علوم پزشکی تبریز

کلمات کلیدی :

Irritable Bowel Syndrome،Probiotics،Pediatrics،Gut Microbiota،Rome IV Criteria،Quality of Life،Lactobacillus rhamnosus GG،Bifidobacterium infantis

چکیده :

Background and Aim: Irritable Bowel Syndrome (IBS) affects 5–15% of children globally, with symptoms including chronic abdominal pain, bloating, and altered bowel habits. Emerging evidence suggests probiotics may restore gut microbiota balance and alleviate symptoms. This study evaluates the efficacy of Lactobacillus rhamnosus GG (LGG) and Bifidobacterium infantis in managing pediatric IBS within a multidisciplinary clinic integrating nutrition and psychology. Methods: A prospective cohort of 150 children (ages 6–16) diagnosed with IBS (Rome IV criteria) was enrolled at a specialized clinic (2022–2024). Participants were stratified into: • Probiotic Group (n=90): Daily LGG (1×10^10 CFU) + B. infantis (5×10^9 CFU) for 6 months. • Standard Care Group (n=60): Dietary modifications + behavioral therapy. Outcomes included symptom resolution (abdominal pain frequency, stool consistency), gut microbiota diversity (16S rRNA sequencing), and quality of life (PedsQL™ 4.0). Data were analyzed using SPSS v28 and R, with significance at p < 0.05. Results: • Symptom Resolution: o 78% of the probiotic group reported ≥50% reduction in abdominal pain vs. 42% in standard care (p = 0.001). o Normal stool consistency (Bristol Scale 3–4) achieved in 85% vs. 55% (p = 0.003). • Microbiota Diversity: o Probiotic group showed a 2.5-fold increase in Bifidobacterium (p = 0.001) and reduced Clostridium levels (OR: 0.4, 95% CI: 0.2–0.8). • Quality of Life: o PedsQL™ scores improved by 35% in the probiotic group vs. 18% (p = 0.01). Conclusion: Probiotic supplementation significantly enhances symptom control, microbiota balance, and psychosocial well-being in pediatric IBS. Multidisciplinary care models combining probiotics, diet, and psychology are critical for optimal outcomes.